 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 6 | 1/1 | 返回列表 |
| 查看: 866 | 回復(fù): 5 | ||
mm1988新蟲 (小有名氣)
|
[求助]
質(zhì)量標(biāo)準(zhǔn)求助 已有2人參與
|
| 碘海醇注射液的質(zhì)量標(biāo)準(zhǔn) Iohexol Injection, BP 、EP |
回復(fù)此樓» 猜你喜歡
請教大佬擴散問題
已經(jīng)有5人回復(fù)
-
中文投稿“腫瘤免疫”相關(guān)
已經(jīng)有6人回復(fù)
-
藥物學(xué)論文潤色/翻譯怎么收費?
已經(jīng)有213人回復(fù)
-
博導(dǎo)推薦
已經(jīng)有2人回復(fù)
-
哪里做甘氨酸受體與配體結(jié)合率的試驗
已經(jīng)有0人回復(fù)
-
2025年藥學(xué)專業(yè)求調(diào)劑
已經(jīng)有1人回復(fù)
-
關(guān)于SCI雜志發(fā)表掛名
已經(jīng)有32人回復(fù)
-
292藥學(xué)調(diào)劑
已經(jīng)有1人回復(fù)
» 本主題相關(guān)價值貼推薦，對您同樣有幫助:
- 質(zhì)量標(biāo)準(zhǔn)的建立
已經(jīng)有3人回復(fù)
- 質(zhì)量標(biāo)準(zhǔn)建立設(shè)計方案
已經(jīng)有3人回復(fù)
- 原研產(chǎn)品相關(guān)質(zhì)量標(biāo)準(zhǔn)信息怎么查詢啊？
已經(jīng)有6人回復(fù)
- 阿立哌唑國外質(zhì)量標(biāo)準(zhǔn)
已經(jīng)有11人回復(fù)
- 求助凝膠劑質(zhì)量檢測標(biāo)準(zhǔn)
已經(jīng)有3人回復(fù)
- 求助原研藥品說明書及質(zhì)量標(biāo)準(zhǔn)
已經(jīng)有4人回復(fù)
- 求助各位一個關(guān)于質(zhì)量標(biāo)準(zhǔn)中有關(guān)物質(zhì)的問題
已經(jīng)有19人回復(fù)
- 卵磷脂質(zhì)量的國際標(biāo)準(zhǔn)
已經(jīng)有7人回復(fù)
- 化工原料的質(zhì)量標(biāo)準(zhǔn)
已經(jīng)有5人回復(fù)
- 藥典質(zhì)量標(biāo)準(zhǔn)翻譯
已經(jīng)有4人回復(fù)
- 塞來昔布原料質(zhì)量標(biāo)準(zhǔn)
已經(jīng)有123人回復(fù)
- 求助關(guān)于質(zhì)量標(biāo)準(zhǔn)有關(guān)物質(zhì)問題
已經(jīng)有15人回復(fù)
- 【求助】關(guān)于質(zhì)量標(biāo)準(zhǔn)研究中液相色譜峰對稱性問題
已經(jīng)有16人回復(fù)
- 【求助】卵磷脂的質(zhì)量標(biāo)準(zhǔn)
已經(jīng)有3人回復(fù)
- 【交流】國家藥典中的質(zhì)量標(biāo)準(zhǔn)是怎么建立起來的？
已經(jīng)有18人回復(fù)
- 【求助】US EPA 制定的土壤重金屬的環(huán)境質(zhì)量標(biāo)準(zhǔn)
已經(jīng)有10人回復(fù)
xdx1984
木蟲 (正式寫手)
- 應(yīng)助: 22 (小學(xué)生)
- 金幣: 3721.7
- 紅花: 12
- 帖子: 471
- 在線: 195.2小時
- 蟲號: 847461
- 注冊: 2009-09-14
- 性別: GG
- 專業(yè): 藥物分析
2樓2015-05-18 13:54:22
【答案】應(yīng)助回帖
★ ★
感謝參與，應(yīng)助指數(shù) +1
mm1988: 金幣+2, ★★★很有幫助, USP38這是在哪里找的，美國藥典論壇嗎？如果是能不能教教我怎么查，注冊了賬號不會查，好慚愧 2015-05-19 09:41:22
感謝參與，應(yīng)助指數(shù) +1
mm1988: 金幣+2, ★★★很有幫助, USP38這是在哪里找的，美國藥典論壇嗎？如果是能不能教教我怎么查，注冊了賬號不會查，好慚愧 2015-05-19 09:41:22
|
USP38 Iohexol Injection DEFINITION Iohexol Injection is a sterile solution of Iohexol in Water for Injection. It contains NLT 95.0% and NMT 105.0% of the labeled amount of iohexol (C19H26I3N3O9) as organically bound iodine. It may contain small amounts of suitable buffers and Edetate Calcium Disodium as a stabilizer. Iohexol Injection intended for intravascular or intrathecal use contains no antimicrobial agents. IDENTIFICATION • A. The retention times of the major peaks of the Sample solution correspond to those of the System suitability solution, as obtained in the test for Organic Impurities. ASSAY • Procedure Sample: A volume of Injection equivalent to 300 mg of iodine Analysis: Transfer the Sample to a glass-stoppered, 250-mL conical flask. Add 25 mL of 1.25 N sodium hydroxide and 500 mg of powdered zinc, connect the flask to a reflux condenser, and reflux the solution for 1 h. Cool the flask to room temperature, rinse the condenser with 20 mL of water, disconnect the flask from the condenser, and filter the mixture. Rinse the flask and the filter thoroughly with small portions of water, adding the rinsings to the filtrate. Add 5 mL of glacial acetic acid, and titrate with 0.1 N silver nitrate VS. Each mL of 0.1 N silver nitrate is equivalent to 27.37 mg of C19H26I3N3O9. Acceptance criteria: 95.0%–105.0% IMPURITIES • Organic Impurities Solution A: Acetonitrile Solution B: Water Mobile phase: The percentage of Solution A increases from 1% to 13% at a rate of 0.2%/min. System suitability solution: 1.5 mg/mL, 0.0075 mg/mL, and 0.0069 mg/mL each of USP Iohexol RS, USP Iohexol Related Compound A RS, and USP Iohexol Related Compound C RS in water Sample solution: 1.5 mg/mL of Iohexol Chromatographic system (See Chromatography 621, System Suitability.) Mode: LC Detector: UV 254 nm Column: 4.6-mm × 25-cm stainless steel column; packing L1 Flow rate: 1.0 mL/min Injection volume: 10 µL System suitability Sample: System suitability solution [Note—The relative retention times for the exo-isomer of iohexol and the O-alkylated compounds are 1.0 and between 1.1 and 1.4, respectively. ] [Note—The peak area of iohexol related compound C is 0.5% ± 0.1% compared to the total area of all the peaks in the chromatogram. ] Suitability requirements Resolution: NLT 20.0 between iohexol related compound A and iohexol related compound C Analysis Sample: Sample solution Excluding peaks with retention times between 0.84 (relative to the endo-isomer of iohexol, which is the first main peak) and 1.0, calculate the percentage of O-alkylated compounds and any other individual impurity peak, in the portion of Iohexol taken: Result = (rU/rT) × 100 rU = = peak response of each impurity rT = = sum of all the peak responses Acceptance criteria Individual impurity: NMT 0.6% of O-alkylated compounds; NMT 0.1% of any other individual impurity Total impurities: NMT 0.3%, excluding O-alkylated compounds SPECIFIC TESTS • Bacterial Endotoxins Test 85: NMT 0.2 USP Endotoxin Unit per 50 mg of iodine • pH 791: 6.8–7.7 • Particulate Matter in Injections 788: The Injection labeled for intrathecal use meets the requirements for small-volume injections. • Free Iodide: Transfer 5.0 mL of Injection to a suitable container, add 20 mL of water, and titrate with 0.001 N silver nitrate VS using a silver electrode in combination with an appropriate reference electrode. Each mL of 0.001 N silver nitrate is equivalent to 0.1269 mg of iodine. Acceptance criteria: NMT 0.02%, based on the content of iohexol • Injections 1: Meets the requirements ADDITIONAL REQUIREMENTS • Packaging and Storage: Preserve Injection intended for intravascular or intrathecal use in single-dose or multiple-dose plastic or Type I glass containers. Store at controlled room temperature, protected from light. Do not freeze. • Labeling: Label containers of Injection to direct the user to discard any unused portion. The labeling states also that it is not to be used if it is discolored or contains a precipitate. Label it also to state its routes of administration. When the specific dose strength is not intended for intrathecal use, label it to indicate “serious injury can occur if given by intrathecal route”. • USP Reference Standards 11 USP Endotoxin RS USP Iohexol RS USP Iohexol Related Compound A RS 5-(Acetylamino)-N,N¢-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide. USP Iohexol Related Compound C RS N,N¢-Bis(2,3-dihydroxypropyl)-5-nitro-1,3-benzenedicarboxamide. |
3樓2015-05-18 16:43:55
mxx7456
新蟲 (小有名氣)
- 應(yīng)助: 22 (小學(xué)生)
- 金幣: 836.9
- 帖子: 113
- 在線: 37.5小時
- 蟲號: 671698
- 注冊: 2008-12-10
- 性別: MM
- 專業(yè): 中藥質(zhì)量評價
4樓2015-05-18 17:18:02
5樓2015-05-19 09:15:37
mm1988
新蟲 (小有名氣)
- 應(yīng)助: 1 (幼兒園)
- 金幣: 447.3
- 散金: 2
- 帖子: 97
- 在線: 68.7小時
- 蟲號: 1397992
- 注冊: 2011-09-11
- 專業(yè): 光譜分析
6樓2015-05-19 09:40:08
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 mm1988 的主題更新
| 6 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 269專碩求調(diào)劑 +5 | 金恩貝 2026-03-21 | 5/250 |
|
|---|---|---|---|---|
|
|
[考研] 0805 316求調(diào)劑 +3 | 大雪深藏 2026-03-18 | 3/150 |
|
|
|
[考研] 求調(diào)劑 +3 | 13341 2026-03-20 | 3/150 |
|
|
|
[考研] 0856材料專碩353求調(diào)劑 +3 | NIFFFfff 2026-03-20 | 3/150 |
|
|
|
[考研] 08工科 320總分 求調(diào)劑 +6 | 梨花珞晚風(fēng) 2026-03-17 | 6/300 |
|
|
|
[考研] 材料工程（專）一志愿985 初試335求調(diào)劑 +3 | hiloiy 2026-03-17 | 4/200 |
|
|
[考研] 304求調(diào)劑 +6 | 曼殊2266 2026-03-18 | 6/300 |
|
|
|
[考研] 一志愿南昌大學(xué)，327分，材料與化工085600 +9 | Ncdx123456 2026-03-19 | 9/450 |
|
|
|
[考研] 一志愿南京理工大學(xué)085701資源與環(huán)境302分求調(diào)劑 +4 | 葵梓衛(wèi)隊 2026-03-18 | 6/300 |
|
|
|
[考研] 求調(diào)劑 +3 | @taotao 2026-03-20 | 3/150 |
|
|
|
[考研] 一志愿南理工085701環(huán)境302求調(diào)劑院校 +3 | 葵梓衛(wèi)隊 2026-03-20 | 3/150 |
|
|
|
[考研] 086500 325 求調(diào)劑 +3 | 領(lǐng)帶小熊 2026-03-19 | 3/150 |
|
|
|
[考研] 招收調(diào)劑碩士 +4 | lidianxing 2026-03-19 | 12/600 |
|
|
|
[考研] 081700化工學(xué)碩調(diào)劑 +3 | 【1】 2026-03-16 | 3/150 |
|
|
|
[考研] 本科鄭州大學(xué)物理學(xué)院，一志愿華科070200學(xué)碩，346求調(diào)劑 +4 | 我不是一根蔥 2026-03-18 | 4/200 |
|
|
|
[考研] 材料，紡織，生物（0856、0710），化學(xué)招生啦 +3 | Eember. 2026-03-17 | 9/450 |
|
|
|
[考研] 生物學(xué)071000 329分求調(diào)劑 +3 | 我愛生物生物愛?/a> 2026-03-17 | 3/150 |
|
|
|
[考博] 26博士申請 +3 | 1042136743 2026-03-17 | 3/150 |
|
|
|
[考研] 085601求調(diào)劑 +4 | Du.11 2026-03-16 | 4/200 |
|
|
|
[考研] 機械專碩325，尋找調(diào)劑院校 +3 | y9999 2026-03-15 | 5/250 |
|